Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications
| Autor: | Ruaraidh Hill, Christian Hierländer, Carolina Zampirolli Dias, Tomasz Bochenek, Ott Laius, Lars L. Gustafsson, Tracey-Lea Laba, Arianit Jakupi, Øyvind Melien, Wija Oortwijn, Luka Voncina, Durhane Wong-Rieger, Caridad Pontes, Jf Hans Piepenbrink, Magdalene Wladysiuk, Guenka Petrova, Patricia Vella Bonanno, Corinne Zara, Robert Sauermann, Steven Simoens, Olayinka O Ogunleye, Amanj Kurdi, Wouter Hamelinck, Wania Cristina Silva, Dzintars Gotham, Seung Jin Bae, Johanna C Meyer, Roberta Joppi, Janet Wale, Admir Malaj, John Yfantopoulos, Gisbert Selke, Angela Timoney, Brian Godman, Vincent de Valk, Andrew Hill, Merce Obach Cortadellas, D Tomek, Hye-Young Kwon, Irene Langner, Jurij Fürst, Iva Selke Krulichová, Antony P. Martin, Jolanta Gulbinovič, Iris Hoxha, Eleonora Allocati, Stuart McTaggart, Ieva Greiciute-Kuprijanov, Vanda Marković-Peković, Ileana Mardare |
|---|---|
| Přispěvatelé: | Godman, Brian, Hill, Andrew, Simoens, Steven, Selke, Gisbert, Laba, Tracey-Lea, Hill, Ruaraidh |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Transparency (market)
Amortization (business) Medical care -- Cost control Alternative pricing approaches cancer medicines europe managed entry agreements minimum effectiveness criteria multicriteria decision analyses payers tiered pricing approaches transparent pricing approaches 0302 clinical medicine Neoplasms Health care Pharmacology (medical) Confidentiality 030212 general & internal medicine Pharmacology & Pharmacy Reimbursement health care economics and organizations Public economics 030503 health policy & services Health Policy General Medicine Europe Models Economic Value (economics) Health Policy & Services Costs and Cost Analysis 0305 other medical science Life Sciences & Biomedicine Scrutiny Cancer -- Treatment -- Europe Antineoplastic Agents Medical care -- Cost control -- Europe Drug Costs Patents as Topic Reimbursement Mechanisms 03 medical and health sciences Drug Development Humans Drugs -- Law and legislation -- Decision making 1115 Pharmacology and Pharmaceutical Sciences 1117 Public Health and Health Services 1402 Applied Economics Science & Technology business.industry lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] Health Care Sciences & Services Sustainability Business RA Delivery of Health Care |
| Zdroj: | Expert review of pharmacoeconomics and outcomes research, Abingdon : Taylor and Francis Ltd., 2021, vol. 21, iss. 4, p. 527-540 Expert Review of Pharmacoeconomics and Outcomes Research, 21, 527-540 EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH Expert Review of Pharmacoeconomics and Outcomes Research, 21, 4, pp. 527-540 Expert review of pharmacoeconomics & outcomes research |
| ISSN: | 1473-7167 1744-8379 |
| Popis: | Introduction: There are growing concerns among European health authorities regarding increasing prices for new cancer medicines, prices not necessarily linked to health gain and the implications for the sustainability of their healthcare systems. Areas covered: Narrative discussion principally among payers and their advisers regarding potential approaches to the pricing of new cancer medicines. Expert opinion: A number of potential pricing approaches are discussed including minimum effectiveness levels for new cancer medicines, managed entry agreements, multicriteria decision analyses (MCDAs), differential/tiered pricing, fair pricing models, amortization models as well as de-linkage models. We are likely to see a growth in alternative pricing deliberations in view of ongoing challenges. These include the considerable number of new oncology medicines in development including new gene therapies, new oncology medicines being launched with uncertainty regarding their value, and continued high prices coupled with the extent of confidential discounts for reimbursement. However, balanced against the need for new cancer medicines. This will lead to greater scrutiny over the prices of patent oncology medicines as more standard medicines lose their patent, calls for greater transparency as well as new models including amortization models. We will be monitoring these developments. peer-reviewed |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|